Therapeutic uses of an insulin secretion enhancer

Abstract

The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.

1 . A method for suppressing hyperglycemia in a non-diabetic subject with IGT and/or IFG comprising administering repaglinide (S)1-[(3-hydroxy-1-adamantyl)amino]-acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof to the subject in need thereof. 
   
   
       2 - 7 . (canceled) 
   
   
       8 . A method of inhibiting or delaying progression to type 2 diabetes in a non-diabetic subject with IGT and/or IFG comprising administering repaglinide (S)1-[(3-hydroxy-1-adamantyl)amino]-acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof to the subject in need thereof. 
   
   
       9 . A method of reducing risk or onset of cardiovascular conditions in a non-diabetic subject with IGT and/or IFG comprising administering repaglinide (S)1-[(3-hydroxy-1-adamantyl)amino]-acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof to the subject in need thereof. 
   
   
       10 . The method according to  claim 1 , or  8 , or  9 , wherein the subject with IGT and/or IFG has prandial glucose excursions having 2 hour plasma glucose values between 7.8 to 11.1 mmol/L after an OGTT or casual glucose test.